https://www.selleckchem.com/TGF-beta.html
Background Deregulation of the PI3K signalling pathway is frequent in squamous cell carcinoma of the head and neck (SCCHN) and may be implicated in radioresistance. We report on the results from a phase I 3 + 3 dose escalation study of alpelisib, a class I α-specific PI3K inhibitor in combination with concurrent cisplatin-based chemoradiation (CRT) in patients with locoregionally advanced SCCHN (LA-SCCHN). Methods Eligible patients had previously untreated LA-SCCHN and were candidates for CRT. The primary objective was to evaluate safety and de
Aimer
Commentaire
Partagez
